Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia? ; volume:38 ; number:11 ; day:10 ; month:9 ; year:2024 ; pages:2376-2381 ; date:11.2024
Leukemia ; 38, Heft 11 (10.9.2024), 2376-2381, 11.2024
- Urheber
-
Stutterheim, Janine
Waarden, Rachella van der
Groot-Kruseman, Hester A. de
Sonneveld, Edwin
Haas, Valérie de
Dandis, Rana
Schoot, C. Ellen van der
Velden, Vincent H. J. van der
Pieters, Rob
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-024-02386-5
- URN
-
urn:nbn:de:101:1-2501172105133.920873178186
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Stutterheim, Janine
- Waarden, Rachella van der
- Groot-Kruseman, Hester A. de
- Sonneveld, Edwin
- Haas, Valérie de
- Dandis, Rana
- Schoot, C. Ellen van der
- Velden, Vincent H. J. van der
- Pieters, Rob
- SpringerLink (Online service)
Ähnliche Objekte (12)
Measurable residual disease
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing
Have we been qualifying measurable residual disease correctly?
Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Measurable residual disease
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing
Have we been qualifying measurable residual disease correctly?
Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Measurable residual disease
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing
Have we been qualifying measurable residual disease correctly?
Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment
Measurable residual disease in multiple myeloma: ready for clinical practice?
Measurable residual disease (MRD)-testing in haematological and solid cancers
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia